Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Docetaxel + Gemcitabine |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Docetaxel | Taxotere | RP56976 | Antimicrotubule Agent 14 | Taxotere (docetaxel) binds to tubulin, inhibiting microtubule disassembly and preventing cell division (PMID: 32496783, PMID: 32366558). |
Gemcitabine | Gemzar | Difluorodeoxycytidine Hydrochlorothiazide|LY-188011 | Chemotherapy - Antimetabolite 14 | Gemzar (gemcitabine) is converted in cells to difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP), which act to inhibit ribonucleoside reductase and as a deoxynucleotide analog respectively, resulting in DNA strand termination and apoptosis (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02045446 | Phase II | Bevacizumab + Erlotinib Docetaxel + Gemcitabine | Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC) | Completed | USA | 0 |
NCT06632327 | Phase III | Docetaxel + Gemcitabine + Nivolumab Cisplatin + Nivolumab + Pemetrexed Disodium Pembrolizumab Carboplatin + Pembrolizumab + Vinorelbine Carboplatin + Nivolumab + Vinorelbine Carboplatin + Gemcitabine Atezolizumab + Carboplatin + Gemcitabine Docetaxel + Gemcitabine Nivolumab Carboplatin + Nivolumab + Pemetrexed Disodium Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Pemetrexed Disodium Cisplatin + Gemcitabine + Nivolumab Atezolizumab + Cisplatin + Vinorelbine Cisplatin + Pembrolizumab + Pemetrexed Disodium Atezolizumab + Carboplatin + Vinorelbine Atezolizumab + Docetaxel + Gemcitabine Cisplatin + Pemetrexed Disodium Carboplatin + Pemetrexed Disodium Carboplatin + Pembrolizumab + Pemetrexed Disodium Cisplatin + Gemcitabine Carboplatin + Gemcitabine + Nivolumab Atezolizumab Carboplatin + Gemcitabine + Pembrolizumab Carboplatin + Vinorelbine Docetaxel + Gemcitabine + Pembrolizumab Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Vinorelbine Cisplatin + Pembrolizumab + Vinorelbine Atezolizumab + Carboplatin + Pemetrexed Disodium | Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Recruiting | USA | 0 |
NCT04145700 | Phase Ib/II | Docetaxel + Gemcitabine + Ramucirumab Docetaxel + Gemcitabine | CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma | Terminated | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT02511132 | Phase II | FANG vaccine Docetaxel + Gemcitabine FANG vaccine + Irinotecan + Temozolomide | A Two-part Phase IIb Trial of Vigil in Ewing's Sarcoma | Completed | USA | 0 |
NCT05999994 | Phase II | Docetaxel + Gemcitabine + Ramucirumab Cyclophosphamide + Ramucirumab + Vinorelbine Cyclophosphamide + Vinorelbine Irinotecan + Temozolomide Abemaciclib + Irinotecan + Temozolomide Docetaxel + Gemcitabine | A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE) | Recruiting | USA | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUS | 1 |
NCT02659020 | Phase Ib/II | Olaratumab Docetaxel + Gemcitabine | A Study of Olaratumab (LY3012207) in Participants With Advanced Soft Tissue Sarcoma | Completed | USA | POL | ITA | ISR | HUN | GBR | FRA | ESP | DEU | AUS | 0 |
NCT06498648 | Phase Ib/II | Abemaciclib + Gemcitabine Docetaxel + Gemcitabine | Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma | Suspended | USA | 0 |
NCT01593748 | Phase II | Docetaxel + Gemcitabine Gemcitabine + Pazopanib | A Treatment Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma | Completed | USA | 0 |
NCT05712694 | Phase III | ADI-PEG 20 + Docetaxel + Gemcitabine Docetaxel + Gemcitabine | Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Recruiting | USA | CAN | 1 |
NCT02049905 | Phase III | Dacarbazine Doxorubicin Ifosfamide Pazopanib Aldoxorubicin Docetaxel + Gemcitabine | Phase 3 Study to Treat Patients With Soft Tissue Sarcomas | Completed | USA | POL | NLD | ITA | ISR | HUN | FRA | ESP | DNK | CAN | AUS | 2 |
NCT03971474 | Phase II | Docetaxel + Gemcitabine + Pemetrexed Disodium Docetaxel + Ramucirumab Docetaxel + Gemcitabine Pembrolizumab + Ramucirumab | Ramucirumab and Pembrolizumab Versus Standard of Care in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer (A Lung-MAP Non-Match Treatment Trial) | Completed | USA | 0 |